Risk factors for gastrointestinal bleeding in patients with acute coronary syndrome
- Authors: Balabanov A.S1, Gordienko A.V1, Serdyukov D.Y.1
-
Affiliations:
- The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
- Issue: Vol 342, No 4 (2021)
- Pages: 47-52
- Section: Articles
- URL: https://journals.eco-vector.com/0026-9050/article/view/82622
- DOI: https://doi.org/10.17816/RMMJ82622
- ID: 82622
Cite item
Open Access
Access granted
Abstract
The article gives an idea of the main risk factors that are predictors of gastrointestinal bleeding in the treatment of patients using double and triple antiplatelet therapy regimens for the acute coronary syndrome. 65 men with the acute coronary syndrome were examined. Most patients have a high prevalence of risk factors for bleeding (over 65 years of age - 80%, arterial hypertension - 49%, renal dysfunction - 57%, anamnesis of the complicated course of peptic ulcer disease - 21.5%) and the need for prophylactic administration of secretolytics. Many patients who underwent percutaneous coronary intervention due to acute coronary syndrome, due to the high risk of gastrointestinal bleeding, should take a long - term therapy with proton pump blockers (omeprazole, rabeprazole). The intake of rabeprazole is preferable for this category of patients due to the smaller number of dyspeptic complaints, a long antisecretory effect, and the optimal cost of the drug.
Full Text
About the authors
A. S Balabanov
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian FederationSaint Petersburg, Russia
A. V Gordienko
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian FederationSaint Petersburg, Russia
D. Yu Serdyukov
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Email: serdukovdu@yandex.ru
Saint Petersburg, Russia
References
- Демографический ежегодник России. 2017 // Стат. сб. - М.: Росстат, 2017. - 264 c.
- Кашталап В.В., Кочергина А.М., Кочергин Н.А. и др. Кровотечения при инвазивной тактике ведения пациентов с острым коронарным синдромом: распространенность, современные подходы к оценке риска и профилактике // Рос. мед. журн. - 2016. - № 12. - С. 739-743.
- Рекомендации ЕОК по ведению пациентов с острым инфарктом миокарда с подъемом сегмента ST - 2017 // Рос. кард. журн. - 2018. - № 23 (5). - С. 103-158.
- Рекомендации ESC/EACTS по реваскуляризации миокарда - 2014 // Рос. кард. журн. - 2015. - № 2 (118). - С. 5-81.
- Шахнович П.Г., Рыжман Н.Н., Черкашин Д.В. Снижение риска геморрагических осложнений у больных с острым инфарктом миокарда // Вест. Рос. воен.-мед. акад. - 2015. - № 3 (51). - С. 195-198.
- Agewall S., Cattaneo M., Collet J.P. et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy // Eur. Heart. J. - 2013. - N 34 (23). - P. 1708-1713.
- Bhatt D.L., Cryer B.L., Contant C.F. et al. Clopidogrel with or without omeprazole in coronary artery disease // N. Engl. J. Med. - 2010. - N 363 (20). - P. 1909-1917.
- Chan F.K. Ching J.Y., Hung L.C. et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding // N. Engl. J. Med. - 2005. - N 352. - P. 238-244.
- Gargiulo G., Costa F., Ariotti S. et al. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial // Am. Heart J. - 2016. - N 174. - P. 95-102.
- Mega J.L., Braunwald E., Wiviott S.D. et al. Rivaroxaban in patients with a recent acute coronary syndrome // N. Engl. J. Med. - 2012. - N 366 (1). - P. 9-19.
- Nikolsky E., Mehran R., Stone G.W. Gastrointestinal Bleeding in Percutaneous Coronary Intervention and Acute Coronary Syndromes // Am. J. Cardiol. - 2009. - N 104. - Р. 22-29.
- Valgimigli M., Bueno H., Byrne R.A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) // Eur. Heart J. - 2017. - N 39. - P. 213-254.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).